A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas®) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment

Transfusion and Apheresis Science

Volumn 35, Issue 3, 2006, Pages 223-233

  Heger, Andrea ^a   Römisch, Jürgen ^a   Svae, Tor Einar ^a  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

Author keywords

Biochemical characterisation; MB plasma; Methylene blue; Octaplas ; Photoinactivation; SD plasma; Solvent detergent; Uniplas; Universal plasma

Indexed keywords

FRESH FROZEN PLASMA; METHYLENE BLUE; PLASMIN INHIBITOR; PROTEIN S;

ARTICLE; BLOOD CLOTTING; PROTEIN ANALYSIS; PROTEIN SYNTHESIS;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PROTEINS; HUMANS; LIGHT; LIPIDS; LIPOPROTEINS; METHYLENE BLUE; PLASMA; PLASMINOGEN; PROTEASE INHIBITORS; REPRODUCIBILITY OF RESULTS; SERINE ENDOPEPTIDASES;

EID: 33751523641     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2006.08.008     Document Type: Article

References (45)

1. Pamphilon D. Viral inactivation of fresh frozen plasma. Br J Haematol 109 (2000) 680-693
2. Mac Lennan S., and Barbara J.A.J. Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol 19 (2006) 169-189
3. Pelletier J.P.R., Transue S., and Snyder E.L. Pathogen inactivation techniques. Best Pract Res Clin Haematol 1 (2006) 205-242
4. Horrowitz B., Bonomo R., Prince A.M., Chin S.N., Brotan B., and Shulman R.V. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 79 (1992) 826-831
5. Wieding J.U., Hellstern P., and Köhler M. Inactivation of viruses in fresh-frozen plasma. Ann Hematol 67 (1993) 259-266
6. Morfeld F., Schütz R., Josic D.J., and Schwinn H. Manufacturing and down scaling process for a virus-inactivated pooled human plasma. Pharm Ind 58 (1996) 433-435
7. Josic D., Schulz P., Biesert L., Hoffer L., Schwinn H., Kordis-Krapez M., et al. Issues in the development of medical products based on human plasma. J Chromatogr B 694 (1997) 253-269
8. Horrowitz B., Lazo A., Grossberg H., Page G., Lippin A., and Swan G. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 74 (1998) 203-206
9. Biesert L., and Suhartono H. Solvent/detergent treatment of human plasma - a very robust method for virus inactivation. Validated virus safety of Octaplas. Vox Sang 74 (1998) 207-212
10. Solheim B.G., Rollag H., Svennevig J.L., Arafa O., Fosse E., and Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion 40 (2000) 84-90
11. Hellstern P., and Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 107 (2002) 3-8
12. Noddeland H., Töllöfsrud S., Svennevig J.L., Bentsen G., Brosstad F., and Solheim B.G. Universal solvent/detergent-treated fresh frozen plasma (Uniplas) - rationale and clinical properties. Thromb Res 107 (2002) 33-37
13. Tollofsrud S., Noddeland H., Svennevig J.L., Bentsen G., Mollnes T.E., and Solheim B.G. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 29 (2003) 1736-1743
14. The Serious Hazards of Transfusion Steering Group. Serious Hazards of Transfusion: (SHOT) - Summary of Annual Report 2001-2002. Manchester; 2003.
15. Riedler G.F., Haycox A.R., Duggan A.K., and Dakin H.A. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 85 (2003) 88-95
16. Silliman C.C., Boshkov L.K., Mohdizadohkashi Z., Elzi D.J., Dickey W.O., Podlosky L., et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 101 (2003) 454-462
17. Lambrecht B., Mohr H., Knüver-Hopf J., and Schnitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 60 (1991) 207-213
18. Williamson L.M., Cardigan R., and Prowse C.V. Methylene blue-treated fresh-frozen plasma: what is the contribution to blood safety?. Transfusion 43 (2003) 1322-1329
19. AuBuchon J.P., Pickard C., Herschel L., O'Connor J.L., and Lee E. Removal of methylene blue from plasma via an adsorbent filter. Vox Sangs 74 (1998) 1-6
20. Riggert J., Humpe A., Legler T.J., Wolf C., Simson G., and Kohler M. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination. Transfusion 41 (2001) 82-86
21. Crettaz D., Sensebe L., Vu D.H., Schneider P., Depasse F., Bienvenut W.V., Quadroni M., and Tissot J.D. Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter. Proteomics 4 (2004) 881-891
22. Hellstern P., Sachse H., Schwinn H., and Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 63 (1992) 178-185
23. Lutze G. Blood clotting factors: determination of activity and concentrationof blood clotting factors in conventional and virus inactivated coagulative plasma. Krankenhauspharmazie 9 (1994) 517
24. Beeck H., and Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 74 (1998) 219-223
25. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11 (2004) 346-350
26. Heger A., Römisch J., and Svae T.E. Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing. Transfus Apher Sci 33 (2005) 257-267
27. Zeiler T., Riess H., Wittmann G., Hintz G., Zimmermann R., Muller C., et al. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 34 (1994) 685-689
28. Aznar J.A., Molina R., and Montoro J.M. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 39 (1999) 748-750
29. Aznar J.A., Bonanad S., Montoro J.M., Hurtado C., Cid A.R., Soler M.A., et al. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang 79 (2000) 156-160
30. Hornsey V.S., Krailadsiri P., MacDonald S., Seghatsian J., Williamson L.M., and Prowse C.V. Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. Br J Haematol 109 (2000) 665-670
31. Seghatchian J., and Krailadsiri P. What's happening? The quality of methylene blue treated FFP and cryo. Tranfusion Apher Sci 25 (2001) 227-231
32. Garwood M., Cardigan R.A., Drummond O., Hornsey V.S., Turner C.P., Young D., et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 43 (2003) 1238-1247
33. Miller C.H., Haff E., Platt S.J., Rawlins P., Drews C.D., Dilley A.B., et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. Thromb Haemost 1 (2003) 2191-2197
34. O'Donell J., and Laffan M.A. The relationship between ABO histo-blood group, factor VIII, and von Willebrand factor. Transfus Med 11 (2001) 343-351
35. Meade T.W., North W.R., Chakrabarti R., Haines A.P., and Stirling Y. Population-based distributions of haemostatic variables. Br Med Bull 33 (1977) 283-288
36. Shimizu A., Saito Y., Matsushima A., and Inada Y. Identification of an essential histidine residue for fibrin polymerization. Essential role of histidine 16 of the Bβ-chain. J Bio Chem 258 (1983) 7915-7917
37. Shimizu A., Saito Y., and Inada Y. Distintive role of histidine-16 of the Bβ-chain of fibrinogen in the end-to-end association of fibrin. Proc Natl Acad Sci 83 (1986) 591-593
38. Henschen-Edman A.H. Photo-oxidation of histidine as a probe for aminoterminal conformational changes during fibrinogen-fibrin conversion. Cell Mol Life Sci 53 (1997) 29-33
39. Lorenz M., Muller M., Jablonka B., Vigh T., and Kirchmaier C.M. High doses of methylene blue/light treatment crosslink the A-alpha-subunit of fibrinogen: influence of this photooxidization on fibrinogen binding to platelets. Haemostasis 28 (1998) 17-24
40. Suontaka A.M., Blomback M., and Chapman J. Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion 43 (2003) 568-575
41. Gill JC. Transfusion principles for congenital coagulation disorder. 2029-38. In: Hoffmann R et al. Hematology - basic principles and practice. 2nd ed. New York: Churchill Livingstone; 1995. ISBN 0-443-08914-0.
42. Atance R., Pereira A., and Ramírez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41 (2001) 1548-1552
43. De La Rubia J., Arriaga F., Linares D., Larrea L., Carpio N., Marty M.L., et al. Role of methylene blue treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 114 (2001) 721-723
44. Alvarez-Larrán A., Río J.D., Ramírez C., Albo C., Pena F., Campos A., et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 86 (2004) 246-251
45. Pereira A. Methylene-blue-photoinactivated plasma and its contribution to blood safety. Transfusion 44 (2004) 948-950